28109-00-4CC(C)c1ccccc1OP(=O)(Oc1ccccc1)Oc1ccccc1C(C)CRMNODSGCFHVNDC-UHFFFAOYSA-N28109-00-4、69500-29-4DTXSID5073616安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Organophosphorus cmpd can produce dermal irritation but most are weak sensitizers. /Organophosphate cmpd/
A woman at 34 to 35 weeks' gestation presented in acute respiratory distress with cyanosis and tachypnea and bilateral rhonchi and crepitation. Her heart rate was 78 beats per minute and her blood pressure 120/80 mm Hg, with a fetal heart rate of 140 beats per minute. The mother was salivating markedly and her pupils were reduced to "pinpoint size." An uncorrected metabolic acidosis was diagnosed. Serum and erythrocyte acetylcholinesterase determinations were near zero. Cholinesterase inhibitor poisoning was felt to be the likely cause of disorders. Administration of atropine 2.4 mg intravenous bolus with infusion of 0.02 mg/kg/hr lead to unacceptable fetal tachycardia. The woman had shown increased cooperativeness and secretion control until the atropine had to be stopped. A cesarean section was performed for delivery of a hypotonic infant with a 1 min Apgar score of 3. The baby was mechanically ventilated for 2 days and required atropine therapy at 0.1 mg/kg/hr for 8 days. The mother required 8 days of mechanical ventilation and 11 days of atropine therapy. In this case, the infant appeared relatively less poisoned than the mother by a presumed organophosphate exposure. /Organophosphate poisoning/
The signs of poisoning due to organophosphorus cmpd are those due to accumulation of acetylcholine & hence overstimulation of parasympathetic nervous system. It is usual to divide them under 3 headings: muscarinic, nicotinic & central. Muscarinic signs ... consist of hypersalivation, lacrimation, sweating & nasal discharge. Miosis, dyspnea, vomiting, diarrhea & frequency of urination ... Nicotinic effects consist of fasciculation of muscles, weakness & paralysis. Central nervous system effects include nervousness, apprehension, ataxia, convulsions & coma. Death is due to resp failure, or sometimes cardiac arrest. There is little difference between signs produced by different organophosphorus compounds, but route of absorption may influence one system more than another. /Organophosphorus cmpd/
現在のフィルター条件では反応記録がありません。
読み込み中…
The potential of isopropyl triphenyl phosphate to produce delayed neurotoxicity in hens was examined using several techniques. Isopropyl triphenyl phosphate contained O,O,O-triphenyl phosphate (24%), O-O-isopropylphenyl O,O-diphenyl phosphate (25%), O,O-diisopropyl-phenyl O-phenyl phosphate (20%), O-O, p-diisopropylphenyl O,O-diphenyl phosphate (18%) and O-p-isopropylphenyl O,O-diphenyl phosphate (6%). Hens treated twice, 3 wk apart, with doses of isopropyl triphenyl phosphate as high as 11.7 g/kg showed no clinical signs of delayed neurotoxicity and only mild signs of general toxicity. Furthermore, none showed even subtle neurohistologic changes suggestive of delayed neurotoxicity. Isopropyl triphenyl phosphate produced dose-dependent inhibition of hen plasma cholinesterase and brain neurotoxic esterase. The study was continued because neurotoxic esterase inhibition has been shown to be a reliable predictor of organophosphates that produce delayed neurotoxicity. Isopropyl triphenyl phosphate was administered prior to tri-o-tolyl phosphate challenge in order to determine if it altered development of tri-o-tolyl phosphate delayed neurotoxicity. Isopropyl triphenyl phosphate neither enhanced nor reduced the onset or severity of neurotoxicity produced by tri-o-tolyl phosphate. The time-course for brain and spinal cord neurotoxic esterase inhibition by isopropyl triphenyl phosphate and tri-o-tolyl phosphate were compared and found to be different. The maximum brain neurotoxic esterase inhibition produced by isopropyl triphenyl phosphate (dose up to 11.7 g/kg) was never complete (always less than 90%), and spinal cord neurotoxic esterase inhibition was significantly less than that produced in the brain. In contrast, brain and spinal cord inhibition produced by 500 mg/kg tri-o-tolyl phosphate were equal and greater than 90%. This testing regimen showed that isopropyl triphenyl phosphate produced an effect on neurotoxic esterase at the biochemical level without producing clinical or neurohistologic abnormalities in treated hens. Furthermore, this biochemical effect was qualitatively different than that produced by the delayed neurotoxicant tri-o-tolyl phosphate. /Isopropyl triphenyl phosphate/
A comatose patient who is diaphoretic, has pinpoint pupils and the odor of an insecticide on clothing or breath, and is noted to have muscle fasciculations represents the classic presentation of organophosphate poisoning. ... Specific steps in management include the following. 1. Decontamination. ... 2 Airway. Establish an airway if necessary. ... 3. Respiratory Status. Respiratory distress, in fact, is commonly found in these patients from multiple causes. ... 4. Cardiac Monitoring. ... 5. Cholinesterase Level. ... 6. Pralidoxime. Pralidoxime is the treatment of choice for organophosphate poisoning and should be used for nearly all patients with clinically significant orgnophosphate poisoning,particularly whose patients with muscular fasciculations and weakness. ... 7. Atropine. Atropine is the physiologic antidote for organophosphate poisoning. A trial dose of atropine should be instituted on clinical ground when one suspects organophosphate intoxication. /Organophosphate poisoning/